Clinical Trial: Oncocyte PADMA

Trial Status: Closed
Disease Type: Lung
Trial ID Oncocyte PADMA
Sponsor ID Oncocyte

Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay, DetermaRXTM, being Considered for Adjuvant Platinum-based chemotherapy or other Adjuvant therapy versus Observation

Principal Investigator
Sandeep J. Khandhar, MD, FACS
1 Location

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 61186372NSC3004
Sponsor ID Paloma 3

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

1 Location
Trial ID 21318
Sponsor ID Roche Laboratories, Inc.

A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Principal Investigator
Timothy A. McCarthy, MD
5 Locations